Mithra sales is not relevant to Mayne pharma go back and read the last update which already shown a return to profitability in 2hfy23 so it is expected a +ve EBITDA in the next update with steady increase in the SP with the buy back etc . that is my analysis according to my calculations EBITDA FY24 $50M THAT IS BASED on no growth in nextstellis sales . they have reps in 50 us states +DTC campaign and ERX partenrship . cost reduction strategies .MARKET PRICE OF A SHARE NEVER BEEN ACCURATE OR A MEASURE OF PERFORMANCE AS THEY GROW SALES AND ADD OTHER PRODUCTS TO THEIR PORTOFLIO THIS WILL SHOW GROWTH
Mithra sales is not relevant to Mayne pharma go back and read...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.03 |
Change
-0.170(3.27%) |
Mkt cap ! $408.6M | |||
| Open | High | Low | Value | Volume |
| $5.20 | $5.21 | $5.03 | $2.804M | 555.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14654 | $5.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.14 | 3111 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |